U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06963216) titled 'A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis' on April 14.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Acquired Factor X Deficiency
Intervention:
BIOLOGICAL: Coagadex(R)
Coagulation Factor X (Human)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kedrion S.p.A.
Published by HT Digital Content Services with permission from Health D...